Global commercial-stage diagnostics firm Oxford Immunotec has started enrolling patients in the PROTECT clinical trial, which is designed to show the clinical value of its T-SPOT.CMV and T-SPOT.PRT products.

The T-SPOT.CMV test is designed to measure the strength of T cell responses to cytomegalovirus (CMV) as a measure of susceptibility to CMV infection.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CMV is a common and serious complication in both solid organ and stem cell transplantation, and the T-SPOT.CMV test is claimed to have the potential to assist clinicians with monitoring antiviral prophylaxis and evaluating patients at risk from this disease.

The company’s T-SPOT.PRT (Panel of Reactive T cells) test measures a patient’s T cell immune response to foreign tissue to assist in the evaluation of risk of graft rejection.

"The T-SPOT.CMV test is claimed to have the potential to assist clinicians with monitoring antiviral prophylaxis and evaluating patients at risk from this disease."

Graft rejection is generally caused by immune responses to the transplanted organ, and both antibody and T cell responses are responsible for rejection events.

See Also:

Designed to complement commonly used antibody tests, the T-SPOT.PRT test provides additional information on the T cell side of the immune system for which currently there are no good measurement tools.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Oxford Immunotec CEO Dr Peter Wrighton-Smith said: "We are pleased to announce that we have begun the enrollment process for our PROTECT study.

"We are excited about the potential application of our T-SPOT.CMV and T-SPOT.PRT products in transplant medicine and the clinical and economic value they could bring to this setting."

Oxford Immunotec is focused on developing and commercialising proprietary tests for management of immune-regulated conditions.